Biotech catalyst, news and analysis PDUFA tracker
Geron Corp
A source-verified Q2 2026 deep dive into Geron, Novavax and Iovance: revenue quality, cash, dilution, pipelines, regulation, competition, valuation and catalysts.
Geron’s latest earnings did not kill the bullish case and did not fully validate it either. What they did was more useful: they forced the story into a more serious phase, where commercial consistency, spending discipline and the coming IMpactMF readout matter more than launch excitement.
The first full commercial year of RYTELO brought ~$184M in revenue and a growing base of prescribing centers, but a softer Q4 versus expectations and unchanged 2026 guidance triggered a sharp pullback in the stock. Here is what actually happened, why the market reacted this way, and how it fits into the long-term thesis we’ve been following on Merlintrader.
Almost one month after our long-form report at around $1.30, Geron is trading near $1.80. A slow but steady grind higher, driven more by positioning and expectations than by new hard data – with the first catalyst window now approaching: Q4 earnings and the first full-year RYTELO outlook under the new CEO.
Geron enters 2026 as a newly minted commercial hematology company with one marketed product, RYTELO (imetelstat), and a late-stage program that could pivot the story from niche LR-MDS anemia to broader myelofibrosis survival if the Phase 3 IMpactMF study delivers.
After decades of telomerase debates and more than one boom-and-bust cycle, Geron finally has an FDA-approved product on the market. Rytelo is generating real revenue, IMpactMF is fully enrolled, and a very loyal retail base is watching every quarterly print and every slide deck, trying to understand whether this is the beginning of a long compounding story or just the payoff of a very long wait.
